235 related articles for article (PubMed ID: 33564898)
1. Incidence risk of PD-1/PD-L1-related pneumonia and diarrhea in non-small cell lung cancer (NSCLC) patients: a systematic review and meta-analysis of randomized controlled trials.
Tong ZQ; Wu DY; Liu D; Dong M
Eur J Clin Pharmacol; 2021 Aug; 77(8):1079-1088. PubMed ID: 33564898
[TBL] [Abstract][Full Text] [Related]
2. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
Kong Y; Hong L; Xu XC; Chen YF; Xu J
PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
[TBL] [Abstract][Full Text] [Related]
3. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
4. Odds ratio of programmed cell death-1 or ligand 1 inhibitor-related endocrine dysfunction in patients with lung cancer: A systematic review and meta-analysis.
Xie J; Zhang Z; Zhang S; Lv Y; Mao Y; Liu R; Tian Y
Medicine (Baltimore); 2019 Dec; 98(50):e18310. PubMed ID: 31852114
[TBL] [Abstract][Full Text] [Related]
5. Network meta-analysis of first-line systemic regimens for older patients with advanced NSCLC.
Luciani A; Dottorini L; Battaiotto E; Petrelli F
Anticancer Drugs; 2024 Jul; 35(6):576-583. PubMed ID: 38527420
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitor.
Ying JM; Yan F
Iran J Kidney Dis; 2024 Mar; 18(2):108-117. PubMed ID: 38660695
[TBL] [Abstract][Full Text] [Related]
7. Oligo-residual disease in PD-1/PD-L1 inhibitor-treated metastatic non-small cell lung cancer: incidence, pattern of failure, and clinical value of local consolidative therapy.
Zhang J; Gao J; Jiang S; Mao J; Chu L; Chu X; Yang X; Li Y; Guo T; Zhou Y; Xu D; Hu J; Chu Q; Ni J; Zhu Z
Cancer Immunol Immunother; 2024 Jun; 73(8):140. PubMed ID: 38833011
[TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review.
Yao Q; Gu L; Su R; Chen B; Cao H
J Cell Mol Med; 2020 Nov; 24(22):13494-13506. PubMed ID: 33078904
[TBL] [Abstract][Full Text] [Related]
10. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors.
Griewing LM; Schweizer C; Schubert P; Rutzner S; Eckstein M; Frey B; Haderlein M; Weissmann T; Semrau S; Gostian AO; Müller SK; Traxdorf M; Iro H; Zhou JG; Gaipl US; Fietkau R; Hecht M
BMC Cancer; 2021 Mar; 21(1):314. PubMed ID: 33761922
[TBL] [Abstract][Full Text] [Related]
11. Toxicity profiles of immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis.
Dang S; Li X; Liu H; Zhang S; Li W
Cancer Med; 2024 Apr; 13(7):e7119. PubMed ID: 38553943
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis.
Mei T; Zhou Q; Gong Y
Clin Oncol (R Coll Radiol); 2024 Feb; 36(2):107-118. PubMed ID: 38151439
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of tumor mutational burden for PD-1/PD-L1 inhibitors in NSCLC: A meta-analysis.
Li W; Zhao Y; Zhang H; Zheng W; Wang R; Gu X
Medicine (Baltimore); 2023 Oct; 102(40):e34990. PubMed ID: 37800825
[TBL] [Abstract][Full Text] [Related]
14. The sound and surprise: overlapping meta-analyses on the topic of safety and efficacy of PD-1 and PD-L1 inhibitors in the treatment of non-small cell lung cancer.
Ou SL; Luo J; Wang S; Li KY; Du SY; Jiang Q
Eur J Clin Pharmacol; 2023 Dec; 79(12):1665-1673. PubMed ID: 37796282
[TBL] [Abstract][Full Text] [Related]
15. Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis.
Tian Y; Huang A; Tian M; Wang K; Dang Q; Zhang C; Liu H; Zhao J; Yang X; Zhang C; Guo L; Chen F
Medicine (Baltimore); 2022 Sep; 101(36):e30151. PubMed ID: 36086680
[TBL] [Abstract][Full Text] [Related]
16. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
Chour A; Basse C; Lebossé F; Bonte PE; Girard N; Duruisseaux M
Lung Cancer; 2024 May; 191():107789. PubMed ID: 38614068
[TBL] [Abstract][Full Text] [Related]
17. Immune-related cardiovascular toxicities of PD-1/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis.
Zhang C; Wei F; Ma W; Zhang J
Front Immunol; 2024; 15():1255825. PubMed ID: 38318172
[TBL] [Abstract][Full Text] [Related]
18. Benefits and risks of PD-1/PD-L1 inhibitors for recurrent small cell lung cancer: A systematic review and meta-analysis.
Zhou J; Du Z; Liang Y; Zhang S
Crit Rev Oncol Hematol; 2024 Jan; 193():104222. PubMed ID: 38036155
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC.
Chen J; Alduais Y; Chen B
Cell Transplant; 2021; 30():9636897211041587. PubMed ID: 34606729
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis.
Huang S; Zheng G; Yang K
World J Surg Oncol; 2023 Nov; 21(1):349. PubMed ID: 37926852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
